MEENAKSHI ANURAG to Drug Resistance, Neoplasm
This is a "connection" page, showing publications MEENAKSHI ANURAG has written about Drug Resistance, Neoplasm.
Connection Strength
1.572
-
Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers. Cell Rep Med. 2025 Jun 17; 6(6):102154.
Score: 0.660
-
Proteogenomic characterization unveils biomarkers associated with chemoresistance in muscle-invasive bladder cancer. Cell Rep Med. 2025 Aug 19; 6(8):102255.
Score: 0.167
-
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Mol Cancer Ther. 2024 Oct 01; 23(10):1494-1510.
Score: 0.157
-
Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer. Cancer Res. 2021 12 15; 81(24):6259-6272.
Score: 0.128
-
Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance). J Natl Cancer Inst. 2020 07 01; 112(7):737-746.
Score: 0.117
-
Endocrine therapy resistance: new insights. Breast. 2019 Nov; 48 Suppl 1:S26-S30.
Score: 0.112
-
Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance Drivers. Clin Cancer Res. 2018 10 01; 24(19):4887-4899.
Score: 0.101
-
Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer. Cancer Discov. 2017 10; 7(10):1168-1183.
Score: 0.096
-
Poziotinib Inhibits HER2-Mutant-Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer. Cancer Res. 2022 08 16; 82(16):2928-2939.
Score: 0.034